4.85 USD
+0.04
0.83%
At close Apr 1, 4:00 PM EDT
After hours
4.85
+0.00
0.00%
1 day
0.83%
5 days
-10.02%
1 month
1.04%
3 months
-25.15%
6 months
24.68%
Year to date
-25.15%
1 year
56.96%
5 years
44.78%
10 years
-97.82%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

439% more call options, than puts

Call options by funds: $399K | Put options by funds: $74K

139% more capital invested

Capital invested by funds: $39.4M [Q3] → $94.1M (+$54.7M) [Q4]

71% more funds holding

Funds holding: 41 [Q3] → 70 (+29) [Q4]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

25% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 12

11.41% more ownership

Funds ownership: 32.54% [Q3] → 43.95% (+11.41%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$9.50
96%
upside
Avg. target
$10.50
116%
upside
High target
$11
127%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Ascendiant Capital
Edward Woo
35% 1-year accuracy
26 / 74 met price target
127%upside
$11
Buy
Maintained
17 Mar 2025
HC Wainwright & Co.
Sean Lee
59% 1-year accuracy
16 / 27 met price target
96%upside
$9.50
Buy
Maintained
12 Mar 2025
Craig-Hallum
Craig Knickerbocker
33% 1-year accuracy
1 / 3 met price target
127%upside
$11
Buy
Maintained
11 Mar 2025

Financial journalist opinion

Based on 5 articles about MYO published over the past 30 days

Neutral
Business Wire
1 day ago
Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24th Annual Needham Virtual Healthcare Conference, being held from April 7th to April 10th, and will be holding one-on-on.
Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference
Negative
Zacks Investment Research
3 weeks ago
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.07 per share a year ago.
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Neutral
Seeking Alpha
3 weeks ago
Myomo, Inc. (MYO) Q4 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the Myomo Fourth Quarter 2024 Earnings Conference Call.
Myomo, Inc. (MYO) Q4 2024 Earnings Call Transcript
Neutral
Business Wire
3 weeks ago
Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of 2023 unless otherwise indicated).
Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million
Neutral
Business Wire
4 weeks ago
Myomo to Report Fourth Quarter 2024 Financial Results on March 10
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chi.
Myomo to Report Fourth Quarter 2024 Financial Results on March 10
Positive
MarketBeat
1 month ago
3 Underrated Robotics Stocks Poised for Major Growth
The days of robots being primarily limited to manufacturing applications are long gone—the industry is expanding rapidly and becoming integrated into many different sectors thanks to rapid developments in AI and automation. Analysts expect this to lead to major growth for the industry in the years to come, with an anticipated CAGR of more than 15% in the coming seven years to reach a size of nearly $170 billion globally by 2032.
3 Underrated Robotics Stocks Poised for Major Growth
Positive
MarketBeat
3 months ago
Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth
As 2025 approaches, several promising micro-cap stocks are gaining attention for their potential to disrupt key industries. These companies, though small in market size, are making significant strides with innovative technologies and strategic advancements.
Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth
Neutral
Business Wire
3 months ago
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
Neutral
Business Wire
3 months ago
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in t.
Myomo, Inc. Announces Proposed Public Offering of Common Stock
Neutral
Seeking Alpha
4 months ago
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™